Last reviewed · How we verify
NCT04045821
Endometrial Rejuvenation Study
NA trial testing AMD3100 in Infertility of Uterine Origin in 3 participants. Terminated before completion.
27 January 2021
Quick facts
| Lead sponsor | Reproductive Medicine Associates of New Jersey |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 3 |
| Start date | 17 January 2020 |
| Primary completion | 27 January 2021 |
| Estimated completion | 4 May 2021 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- AMD3100 — full drug profile →
- Normal saline
- dilation and curettage
Conditions studied
- Infertility of Uterine Origin — all drugs for Infertility of Uterine Origin →
Sponsor
Reproductive Medicine Associates of New Jersey — full company profile →
Who can join
Adults 18 to 55, female only, with Infertility of Uterine Origin. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the response of the endometrial lining after subcutaneous administration of the medication AMD3100. This medication mobilizes stem cells and will be used in a population of infertile women with a thin endometrium who are undergoing frozen-thawed embryo transfer. The investigators will assess associations between response to stem cell mobilization and pregnancy outcomes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04045821
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of AMD3100
Trials testing the same drug.
- NCT04058145 — AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma · Phase 2 · withdrawn
- NCT00322127 — An Evaluation of Safety and Efficacy of Escalating Doses of AMD3100 to Mobilize CD34+ Cells in Healthy Volunteers · Phase 1 · completed
Other Reproductive Medicine Associates of New Jersey trials
Trials by the same sponsor.
- NCT06074055 — PRogrammed Versus Modified Natural Cycle After Euploid Failed Embryo Transfer · NA · terminated
- NCT05853822 — FirmTech User Research Trial · completed
- NCT05397912 — Uterine Elastography: a Potential Predictor of Embryo Transfer Success · completed
- NCT04852029 — Prospective Assessment of Impact of Personalized Dosing of Low-dose Human Chorionic Gonadotropin (hCG) on in Vitro Ferti · NA · terminated
- NCT04693806 — The Effect of Embryo Culture Under a Continuous CO2 Setting Versus a Sequential CO2 Setting · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04045821 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Reproductive Medicine Associates of New Jersey
- Last refreshed: 19 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04045821.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing